Publisher’s Spotlight: Citeline News And Insights App

Introducing the all-new Citeline News and Insights app, providing seamless access to all your favorite award-winning publications. Explore the latest articles from Pink Sheet, Scrip, In Vivo, Medtech Insight, Generics Bulletin and HBW Insight, all in one stylish, intuitive and user-friendly platform.

Pink Sheet Mobile App
• Source: Shutterstock

Enjoy a faster, streamlined experience, tailor-made for your mobile device – now available on the App Store and Google Play.

Effortlessly switch between publications, customize your home screen, and search for articles across the full suite of Citeline publications. Stay up to date with breaking news notifications and save offline articles for later with the personalized 'my content' feature, ensuring you never miss a beat.

This is the new way to experience your news and insights.

  • Seamless Experience: The mobile-native app provides streamlined access to all Citeline’s news and insights publications.
  • Swipe and Customize: Effortlessly switch between publications and customize your experience, ensuring you only see what matters most.
  • Detailed Search: Discover the latest insights at your fingertips, searching the latest articles across multiple publications.
  • Anytime, Anywhere: Bookmark articles for later, even offline! Access your saved articles in "My Content" for reading anytime, anywhere.
  • Endless Connectivity: Enjoy a hassle-free experience – once logged in, stay connected even when switching to the browser version of the publication.

More from Archive

More from Pink Sheet

Global Pharma Guidance Tracker - April 2025

 

Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Medicare Negotiation Does Not Violate Due Process, Appeals Court Rules, Other Suits At Risk

 
• By 

Decision in AstraZeneca’s lawsuit against the Health and Human Services Department is a precedent-setting victory for the government and a blow to manufacturer efforts to block the price negotiation program.

Keep Talking: US FDA’s Beleaguered Biologics Center Remains Vital To Regenerative Medicine

 

Advisory committee for Capricor’s deriamocel planned, regenerative medicine advanced therapy designations proliferate for osteoarthritis, and the ranks of dual RMAT/breakthrough therapy designation holders grow.